Acurx Pharmaceuticals Inc... (ACXP)
NASDAQ: ACXP
· Real-Time Price · USD
5.11
0.25 (5.14%)
At close: Aug 15, 2025, 3:59 PM
5.12
0.20%
After-hours: Aug 15, 2025, 05:58 PM EDT
Acurx Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -4.39B | -2.15M | -2.78M | -2.82M | -4.12M | -4.38M | -5.12M | -3.11M | -3.44M | -2.9M | -3.26M | -3.54M | -2.62M | -2.67M | -2.63M | -4.64M | -4M | -1.47M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Stock-Based Compensation | 657.37M | 443.68K | 538.37K | 317.56K | 1.02M | 1.2M | 1.23M | 833.28K | 806.49K | 899.38K | 696.97K | 824.04K | 716.68K | 949.17K | 581.4K | 3.4M | 2.26M | 327.14K |
Other Working Capital | n/a | -397.11K | 171.83K | -47.85K | -31.63K | -14.33K | -310.15K | -15.78K | 1.06M | -12.3M | -265.32K | 537.5K | 283.23K | 210.73M | -21.23K | -1.39M | 1.48M | -316.71K |
Other Non-Cash Items | 3.73B | 306.00 | -49.05K | 440.32K | 256.63K | 169.00 | 153.00 | 203.48K | 945.43K | 899.38K | 812.47K | 708.2K | -159.15K | -210.88K | 310.21K | 46.07K | -66.5K | 916.76K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | 346K | -345.98K | 42.67K | -125.88K | -31.63K | 114.83K | -310.15K | -15.78K | 116.66K | 70.65K | 952.46K | -171K | 72.35K | -155K | 366.75K | -1.39M | 1.48M | -317K |
Operating Cash Flow | -1.67M | -2.05M | -2.25M | -2.19M | -2.88M | -3.06M | -4.2M | -2.09M | -1.58M | -1.93M | -1.5M | -2.18M | -1.99M | -1.88M | -1.5M | -2.64M | -330K | -547K |
Capital Expenditures | 4.00 | n/a | n/a | n/a | n/a | -5 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | 610.26M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | -327 | n/a | -475 | n/a | 211K | 2.22M | 3.54M | 73.00 | n/a | -3.7M | 3.7M | n/a | n/a | 14.78B | n/a | n/a | n/a |
Financial Cash Flow | 3.09M | 2.99M | 194.55K | 1.59M | 320.21K | 4.51M | 4.62M | n/a | 3.54M | n/a | -1 | 3.69M | n/a | n/a | 14.78B | n/a | 14.8M | n/a |
Net Cash Flow | 1.42M | 937.17K | -2.06M | -598K | -2.56M | 1.45M | 421.86K | -2.09M | 1.97M | -1.93M | -1.5M | 1.51M | -1.99M | -1.88M | -1.5M | -2.64M | 14.47M | -547K |
Free Cash Flow | -3.72B | -2.05M | -2.25M | -2.19M | -2.88M | -3.06M | -4.2M | -2.09M | -1.58M | -1.93M | -1.5M | -2.18M | -1.99M | -1.88M | -1.5M | -2.64M | -330K | -547K |